Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
about
Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directionsPathogenesis, management and prevention of atypical femoral fracturesChildhood obesity, bone development, and cardiometabolic risk factorsEstablishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bonesPeriprosthetic bone loss: diagnostic and therapeutic approachesAmerican Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.Advanced Glycation End Products, Diabetes, and Bone StrengthHeterogeneous glycation of cancellous bone and its association with bone quality and fragilityAdvanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic MiceChanges in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control StudyBisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.Bisphosphonates and bone quality.The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronateBisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependentSkeletal effects of zoledronic acid in an animal model of chronic kidney diseaseIn situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption.Biological regulation of bone quality.Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged ratsDuration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogsQuestioning the association between bisphosphonates and atypical femoral fracturesFocal therapeutic irradiation induces an early transient increase in bone glycation.Non-enzymatic glycation alters microdamage formation in human cancellous bone.Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous boneAssociation between non-enzymatic glycation, resorption, and microdamage in human tibial cortices.Atypical femoral fractures: epidemiology, etiology, and patient managementEffects of bone matrix proteins on fracture and fragility in osteoporosis.Solid state NMR investigation of intact human bone quality: balancing issues and insight into the structure at the organic-mineral interfaceMatrix metalloproteinase-13 is required for osteocytic perilacunar remodeling and maintains bone fracture resistance.Circulating osteogenic precursor cells in type 2 diabetes mellitus.Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.Determinants of bone strength and quality in diabetes mellitus in humans.Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in low- and high energy fracture conditionsReference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing.Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Advanced Glycation End-products and Bone FracturesShort-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness.Effect of a local, one time, low-dose injection of zoledronic acid on titanium implant osseointegration in ovariectomized rats
P2860
Q26750574-51A8EB84-C26B-4C91-9954-1652A01503CEQ26824555-7A527A9E-1F76-4D64-8DAD-43FA0FF1180BQ26853091-D39567EA-0089-4B05-AD40-4CAA228BC66FQ26861856-516B036F-66E3-4367-93A1-918D71E599D1Q27024847-AEC3429B-E17D-43A3-89A9-97F9A6DF73E6Q27027254-B4DA657D-53B4-48D1-BC89-DDCAC805DF1EQ28076977-28438728-4C54-4119-A8B4-6EBF52A168C7Q28482286-0AE12DAE-BE40-4044-B7CC-2B479E95D84FQ28551744-C49C2F07-E53F-4241-BA84-D96904D6FD4DQ30873913-B7128875-80BD-4C61-8CC2-1A5806FB7A48Q33552108-2E97CC7C-A823-42BA-AFAF-AE31E123FFB9Q33665130-36A2A4B0-E3D0-4771-BC65-FB2D43E7EE2FQ33683219-C97E24D7-E953-4F3C-A9C3-1072084C02B5Q33700394-C4D86B08-3C08-43FE-A06F-BF2EB2F2723EQ33723995-F5E90451-3B9C-43F5-A23C-106BE9E6D76AQ33779709-F3F19D22-45F2-4BDA-AB73-EA38551A853CQ33885263-8C45E5D6-79C5-4032-B9B2-5593E2D291AEQ34051287-5BD27FEF-4F0A-41A1-B34F-ED8E6BC35B8EQ34283690-18386337-98B8-4242-AE21-4A968AD57DDEQ34411999-B4ABCB4E-12E6-463E-8177-0A1DA153BEDBQ34758541-489ACA3C-5F36-47B6-BD32-DFE5BFA09FFDQ34899110-8C3E3A60-031C-4D64-99C7-08A2CD6831FAQ35245623-EC105A49-279E-4E43-810F-CC760AB3FA0DQ35429148-261CB8ED-7C6B-4A9B-8511-7DBB6129B976Q35505244-682E495A-820B-4A90-BE5A-C5EDD6BB4929Q35997620-F5B3D515-8119-4509-B9BE-00B387FDF688Q36010491-D3E36A5D-2A2D-485F-A3B7-E007D18DC432Q36016579-B810D207-8D8F-4D0B-8A23-0C8C1B05CF0DQ36032326-29E24340-6517-43A9-878D-E5A37323564BQ36102647-6B4DC6ED-955E-4E1D-A765-18AA5EF9C120Q36153043-70E8DB0F-E5ED-4FA6-AB73-FD25B9B66D41Q36201509-91FA7E10-4A34-470A-BDDD-799D57B9D92FQ36372679-1530EBC8-488E-40EB-AA7B-ED0DABCE7837Q36373016-334D298A-B8CF-4336-992A-DA3C2AF03832Q36583064-63BA9BFF-40B1-4763-92F5-A0A5267F529FQ36584474-5E075BFF-DC74-4285-946C-8CCC27755B45Q36633388-211B5919-519B-40EF-B143-FA730BDCECE2Q36868071-C7E426FF-E5D7-475D-ABBE-E50C995F307FQ37067163-48E804C5-6914-49A1-9CDB-2E4B74B7275AQ37243041-0F05C699-8671-415F-9B9C-673A19B555B0
P2860
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Changes in non-enzymatic glyca ...... th risedronate or alendronate.
@en
Changes in non-enzymatic glyca ...... th risedronate or alendronate.
@nl
type
label
Changes in non-enzymatic glyca ...... th risedronate or alendronate.
@en
Changes in non-enzymatic glyca ...... th risedronate or alendronate.
@nl
prefLabel
Changes in non-enzymatic glyca ...... th risedronate or alendronate.
@en
Changes in non-enzymatic glyca ...... th risedronate or alendronate.
@nl
P2093
P2860
P1476
Changes in non-enzymatic glyca ...... ith risedronate or alendronate
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-008-0754-4
P407
P577
2008-10-11T00:00:00Z